What’s going on inside Biogen?
When Ted Whitford read last week’s news that Biogen was reviving an Alzheimer’s disease treatment once thought hopeless, he thought back to 2013.
Back then, Whitford worked at Biogen, which was deeply invested in a potential treatment for amyotrophic lateral sclerosis. When that drug, dexpramipexole, proved no better than placebo, it was devastating for employees like Whitford, to say nothing of the many patients given hope by its earlier promise. What Whitford remembers with pride, however, was Biogen’s promise not to mine the data for a flimsy excuse to keep dexpramipexole alive, a decision made out of sense of responsibility to patients and their families.
The hope, Whitford writes in STAT, is that Biogen’s recent move in Alzheimer’s is truly based on scientific promise and not a reversal of its principled stand in ALS.
Read more.
Back then, Whitford worked at Biogen, which was deeply invested in a potential treatment for amyotrophic lateral sclerosis. When that drug, dexpramipexole, proved no better than placebo, it was devastating for employees like Whitford, to say nothing of the many patients given hope by its earlier promise. What Whitford remembers with pride, however, was Biogen’s promise not to mine the data for a flimsy excuse to keep dexpramipexole alive, a decision made out of sense of responsibility to patients and their families.
The hope, Whitford writes in STAT, is that Biogen’s recent move in Alzheimer’s is truly based on scientific promise and not a reversal of its principled stand in ALS.
Read more.
No hay comentarios:
Publicar un comentario